Synpromics will develop synthetic promoters for use with Avalanche’s Ocular BioFactoryTM platform technology. Synpromics' technology creates highly specific promoters that control gene expression. These promoters are designed to be specific to the target cell type and aim to enable a precise level of control of gene expression.
Dr David Venables, CEO of Synpromics, commented, “This is our fourth collaboration in the field of gene therapy and further validation of the wide applicability of our platform. Avalanche Biotechnologies is developing next generation gene therapy technologies to treat eye diseases and we believe that Synpromics’ technology has the potential to support the development of these next generation therapeutics.”